Evidence map›Paper›PMID 25082656›Full record

Trial reportClinical and experimental nephrology2015

The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients.

Dilara Bayram, M Tuğrul Sezer, Salih İnal, Atila Altuntaş, Veysel Kıdır, Hikmet Orhan

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical and experimental nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 6 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 6 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Efficacy of Allopurinol in Improving Endothelial Dysfunction: A Systematic Review and Meta-Analysis.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. The effects of topiroxostat on vascular function in patients with hyperuricemia.Journal of clinical hypertension (Greenwich, Conn.) · 2019
    Article
  11. Observational
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Dilara BayramDepartment of Internal Medicine, Süleyman Demirel University Faculty of Medicine, Isparta, Turkey.
M Tuğrul SezerDivision of Nephrology, Department of Internal Medicine, Süleyman Demirel University Faculty of Medicine, Cunur, 32200, Isparta, Turkey.
Salih İnalDivision of Nephrology, Department of Internal Medicine, Süleyman Demirel University Faculty of Medicine, Cunur, 32200, Isparta, Turkey. salihinal@yahoo.com.
Atila AltuntaşDivision of Nephrology, Department of Internal Medicine, Süleyman Demirel University Faculty of Medicine, Cunur, 32200, Isparta, Turkey.
Veysel KıdırDivision of Nephrology, Department of Internal Medicine, Süleyman Demirel University Faculty of Medicine, Cunur, 32200, Isparta, Turkey.
Hikmet OrhanDepartment of Biostatistics and Medical Informatics, Süleyman Demirel University Faculty of Medicine, Isparta, Turkey.
Suleyman Demirel University · KZSüleyman Demirel University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperuricemia and metabolic acidosis have emerged as important risk factors for progression of kidney disease. In this study, we aimed to investigate the effects of allopurinol on metabolic acidosis and endothelial functions in hyperuricemic stage 2-4 chronic kidney disease (CKD) patients.

methodsThirty patients with stage 2-4 CKD and serum uric acid levels over 5.5 mg/dl were included in the study group. They were prescribed 300 mg/day per oral allopurinol treatment for three months. Age- and gender-matched CKD patients (n = 30) with similar clinical characteristics were taken as the control group and were not given allopurinol treatment. Endothelial functions were measured via flow-mediated dilatation (∆FMD %) over the forearm. pH and HCO3 levels in venous blood, Cr clearance and proteinuria levels were calculated in all patients at baseline and in the third month.

resultsSerum uric acid levels significantly decreased in the study group from 7.9 ± 1.6 to 6.4 ± 1.7 (p < 0.001). Cr clearance (from 43.4 ± 20.1 to 51.4 ± 24.9, p = 0.011), serum bicarbonate levels (from 21.4 ± 3.4 to 23.0 ± 3.4, p = 0.007) and ΔFMD % values (from 5.8 ± 2.5 to 6.2 ± 2.7, p = 0.006) increased significantly in the allopurinol group. There were no significant changes except for ∆FMD % values (decreased from 6.27 ± 1.62 to 5.71 ± 1.90, p = 0.005) in the control group. ∆FMD % variations within the two groups were clearly significant in the repeated ANOVA general linear model.

conclusionWe assume that decreasing uric acid levels with allopurinol treatment seems to be helpful in restoring endothelial functions, preventing metabolic acidosis and slowing down the progression of CKD.

Indexed as

AcidosisAdultAgedAllopurinolBicarbonatesCreatinineEndotheliumFemaleGout SuppressantsHumansHyperuricemiaMaleMiddle AgedProspective StudiesRenal Insufficiency, ChronicUric AcidAllopurinolBicarbonatesCreatinineGout SuppressantsUric AcidAllopurinolChronic kidney diseaseEndothelial dysfunctionHyperuricemiaMetabolic acidosis

Identifiers

PMID25082656
OpenAlexW1993196376

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.